SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis

Berardis, Silvia; Verroken, Alexia; Vetillart, A.; Struyf, Catherine; Gilbert, Marie; Gruson, Damien; Gohy, Sophie

doi:10.1016/j.jcf.2020.08.005

Cited by 22 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We cannot rule out that the testing strategy during the first phase of the pandemic, with only symptomatic patients being tested by PCR and limited use of serological tests, could have led to an underestimation of the real infection rate. However, seroprevalence data from Belgium seem to confirm the low infection rate in the CF population [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020

et al. 2021

View full text Add to dashboard Cite

Objective To describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF). Methods We carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to collect baseline and follow-up data of patients who reported symptoms suggestive of COVID-19 or who had contact with a positive/suspected case between the end of February and July 2020. Symptoms and clinical course of the infection were compared between patients who tested positive by molecular testing (cases) and those who tested negative (controls). Results Thirty patients were reported from the centres, 16 of them tested positive and 14 tested negative. No differences in symptoms and outcome of the disease were observed between groups. Fever, cough, asthenia and dyspnea were the most frequently reported symptoms. Eight cases (50%) were hospitalized but none required ICU admission. Two adults with a history of lung transplant required non-invasive ventilation, none required ICU admission and all patients fully recovered without short-term sequelae. Conclusions The course of SARS-CoV-2 in our patients was relatively favorable. However, COVID-19 should not be considered a mild disease in CF patients, particularly for those with severely impaired respiratory function and organ transplant.

show abstract

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Another study conducted in Belgium evaluated 149 patients with CF between April and May 2020 and measured their anti-SARS-CoV-2 IgM and IgG levels. A lower seroprevalence was noted in individuals with CF (2.7%) versus the general population (4.9%), suggesting a lower infection rate [14] . An overview study conducted in Italy concluded that the infection rate was indeed lower in the CF population than that of the general population [15] , [16] .…”

Section: Epidemiology Of Sars-cov-2 In Cystic Fibrosismentioning

confidence: 82%

“…However, data suggest that the SARS-CoV-2 infection rate is lower in those with CF compared to the general population [11] , [12] , [13] , [14] , [15] , [16] . This is likely the result of rigorous infection control measures practiced by the CF community.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes

Mason¹,

Hasan²,

Darukhanavala³

et al. 2021

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

The novel SARS-CoV-2 coronavirus (COVID-19) has become a global health crisis since its initial outbreak in Wuhan, China in December 2019. On January 30, 2020, the WHO recognized the COVID-19 outbreak as a Public Health Emergency, and on March 11, 2020, it was declared a pandemic. Although all age groups have been affected, patients with cystic fibrosis (CF) and patients with diabetes have been categorized as highly vulnerable to SARS-CoV-2 infection. Thus far, studies have found that the incidence of SARS-CoV-2 in the CF population is lower than the general population. We review the underlying protective mechanisms which may reduce inflammation and lung damage in CF patients, thus decreasing their risk of severe COVID-19. While the effect of SARS-CoV-2 in those with diabetes related to CF is unknown, other forms of diabetes have been associated with more severe disease. To further understand the potential impact of SARS-CoV-2 in cystic fibrosis-related diabetes, we provide a comprehensive overview of the potential factors contributing to COVID-19 severity in other forms of diabetes, including direct viral effect on the pancreas and indirect effects related to hyperglycemia and immune dysregulation.

show abstract

“…While it was clear that COVID-19 could be a serious condition for some people with CF, infection with SARS-CoV-2 for most people with CF is less severe than originally feared. We have also learned that there can be asymptomatic infection, with evidence coming from serologic assessment of a CF cohort [4] , although the prevalence was low, perhaps lower than the general population. One hypothesis for this observation is that CF patients and families are more attuned to the need for infection control measures and are therefore better at shielding themselves to minimize the risks of infection.…”

mentioning

confidence: 99%